<DOC>
	<DOC>NCT01855139</DOC>
	<brief_summary>The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.</brief_summary>
	<brief_title>Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patients ≥ 18 years old with a confirmed diagnosis of nonvalvular atrial fibrillation Patients must in addition present with at least one of following risk factors: prior stroke, TIA (transient ischemic attack) or nonCNS (central nervous system) systemic embolism left ventricular ejection fraction of &lt; 40% symptomatic heart failure, New York Heart Association class 2 or higher age ≥75 years age ≥65 years in combination with either diabetes, coronary disease or arterial hypertension Patients who do not fulfil the Belgian reimbursement criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Systemic embolism</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Real-life setting</keyword>
	<keyword>Preventive measure</keyword>
</DOC>